342 related articles for article (PubMed ID: 34552244)
21. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
22. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
23. Advancing precision medicine for prostate cancer through genomics.
Roychowdhury S; Chinnaiyan AM
J Clin Oncol; 2013 May; 31(15):1866-73. PubMed ID: 23589550
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.
Logan IR; McNeill HV; Cook S; Lu X; Lunec J; Robson CN
Prostate; 2007 Jun; 67(8):900-6. PubMed ID: 17440969
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
26. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.
Friedlander TW; Pritchard CC; Beltran H
Am Soc Clin Oncol Educ Book; 2017; 37():358-369. PubMed ID: 28561699
[TBL] [Abstract][Full Text] [Related]
27. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.
Miyamoto DT; Zheng Y; Wittner BS; Lee RJ; Zhu H; Broderick KT; Desai R; Fox DB; Brannigan BW; Trautwein J; Arora KS; Desai N; Dahl DM; Sequist LV; Smith MR; Kapur R; Wu CL; Shioda T; Ramaswamy S; Ting DT; Toner M; Maheswaran S; Haber DA
Science; 2015 Sep; 349(6254):1351-6. PubMed ID: 26383955
[TBL] [Abstract][Full Text] [Related]
28. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
29. [Recent advances on molecular pathology of prostate carcinoma].
Niu HL; Tao Y
Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
[TBL] [Abstract][Full Text] [Related]
30. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
[TBL] [Abstract][Full Text] [Related]
31. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
Xu L; Yin Y; Li Y; Chen X; Chang Y; Zhang H; Liu J; Beasley J; McCaw P; Zhang H; Young S; Groth J; Wang Q; Locasale JW; Gao X; Tang DG; Dong X; He Y; George D; Hu H; Huang J
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753479
[TBL] [Abstract][Full Text] [Related]
32. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
33. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract][Full Text] [Related]
34. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
35. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
37. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
38. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Beltran H; Antonarakis ES; Morris MJ; Attard G
Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
[TBL] [Abstract][Full Text] [Related]
39. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
40. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
